Lung function trajectory in progressive fibrosing interstitial lung disease. Issue 6 (16th June 2022)

• Record Type: Journal Article
• Authors: Oldham, Justin M.; Lee, Cathryn T.; Wu, Zhe; Bowman, Willis S.; Pugashetti, Janelle Vu; Dao, Nam; Tonkin, James; Seede, Hasan; Echt, Gabrielle; Adegunsoye, Ayodeji; Chua, Felix; Maher, Toby M.; Garcia, Christine K.; Strek, Mary E.; Newton, Chad A.; Molyneaux, Philip L.
• Is Part Of: European respiratory journal. Volume 59:Issue 6(2022)
• Publication Date: 2022-06-16
• Subjects: Respiratory organs -- Diseases -- Periodicals; Respiration -- Periodicals; 616.2
• DOI: 10.1183/13993003.01396-2021
• Languages: English
• ISSNs: 0903-1936

Abstract

Background: Proposed criteria for progressive fibrosing interstitial lung disease (PF-ILD) have been linked to increased mortality risk, but lung function trajectory after satisfying individual criteria remains unknown. Because survival is rarely employed as the primary end-point in therapeutic trials, identifying PF-ILD criteria that best predict subsequent change in forced vital capacity (FVC) could improve clinical trial design. Methods: A retrospective, multicentre longitudinal cohort analysis was performed in consecutive patients with fibrotic connective tissue disease-associated ILD (CTD-ILD), chronic hypersensitivity pneumonitis and idiopathic interstitial pneumonia at three US centres (test cohort) and one UK centre (validation cohort). 1-year change in FVC after satisfying proposed PF-ILD criteria was estimated using joint modelling. Subgroup analyses were performed to determine whether results varied across key subgroups. Results: 1227 patients were included, with CTD-ILD predominating. Six out of nine PF-ILD criteria were associated with differential 1-year change in FVC, with radiological progression of fibrosis, alone and in combination with other features, associated with the largest subsequent decline in FVC. Findings varied significantly by ILD subtype, with CTD-ILD demonstrating little change in FVC after satisfying most PF-ILD criteria, while other ILDs showed significantly larger changes. Findings did not vary after stratification by radiological pattern or exposure to immunosuppressant therapy. Near-term change in FVC after satisfying proposed PF-ILD criteria was heterogeneous depending on the criterion assessed and was strongly influenced by ILD subtype. Conclusions: These findings may inform future clinical trial design and suggest ILD subtype should be taken into consideration when applying PF-ILD criteria. Lung function trajectory varies considerably following ILD diagnosis and after satisfying proposed PF-ILD criteria according to ILD diagnosis. These findings suggest diagnosis should be taken into consideration when designing ILD clinical trials. https://bit.ly/2ZF8C7V